SCHEMBL3575937

SCHEMBL3575937

CCOC(=O)Cc1n[nH]c(=O)n1-c1ccc(Br)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DUSP3 P51452 1/20 0.46
MAPT P10636 5/20 0.43
RECQL P46063 1/20 0.43
JAK2 O60674 1/20 0.42
PAK4 O96013 1/20 0.42
NTRK1 P04629 1/20 0.42
LCK P06239 1/20 0.42
FYN P06241 1/20 0.42
CSF1R P07333 1/20 0.42
RET P07949 1/20 0.42
MET P08581 1/20 0.42
PDGFRB P09619 1/20 0.42
PIM1 P11309 1/20 0.42
FGFR1 P11362 1/20 0.42
PRKACA P17612 1/20 0.42
GRK5 P34947 1/20 0.42
MAP2K2 P36507 1/20 0.42
FLT3 P36888 1/20 0.42
MAPK8 P45983 1/20 0.42
CDK8 P49336 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL763265 0.75 TDP1 (0.66) DUSP3GAAPOLBTDP1KDM4E
SCHEMBL2357776 0.71 FASN (0.52) DUSP3MAPTSMN1; SMN2GAA
SCHEMBL4733 0.68 CYP1A2 (0.55) MAPTSMN1; SMN2ALDH1A1POLBCYP2C9
SCHEMBL2358613 0.68 FASN (0.60) MAPTCYP2C19ALDH1A1GAACYP2C9
Ethyl Acetate SCHEMBL27682430 0.67 DUSP3 (0.45) DUSP3MAPTCYP2C19ALDH1A1GAA
SCHEMBL2300325 0.66 FASN (0.67) SMN1; SMN2
SCHEMBL1905681 0.66 MEN1 (0.60) MAPTALDH1A1POLBKDM4EHTT
SCHEMBL24779697 0.66 DUSP3 (0.44) DUSP3MAPTSMN1; SMN2ALDH1A1GAA
SCHEMBL3158838 0.65 MAPT (0.61) MAPTSMN1; SMN2ALDH1A1GAAPOLB
SCHEMBL23908895 0.65 SMN1; SMN2 (0.70) MAPTJAK2PAK4NTRK1LCK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100029620-A1 SUBSTITUTED TRIAZOLINE, TETRAZOLONE AND IMIDAZOLONE DERIVATIVES FOR USE AS A MEDICINE JANSSEN PHARMACEUTICA N.V. 2010-02-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100029620-A1 SUBSTITUTED TRIAZOLINE, TETRAZOLONE AND IMIDAZOLONE DERIVATIVES FOR USE AS A MEDICINE ADRA2C, ADRB2, CHRNA5 DUSP3 2278/4885MAPT 175/4885RECQL 3786/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.